Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Rhea-AI Summary

Eledon (Nasdaq: ELDN) announced that Steven Perrin, Ph.D., President and Chief Scientific Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 at 10:00 a.m. ET (7:00 a.m. PT).

According to the company, the session will be webcast live with a replay available afterward on Eledon’s website under Events.

News Market Reaction – ELDN

+11.17%

+11.17% Session close to close

In the Feb 6 session, ELDN gained 11.17%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +11.2% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +11.2% in the session following this news. A strong positive reaction aligns with the pattern of frequent news flow around clinical progress and conference visibility but would contrast with prior muted or negative moves after announcements. Investors would need to weigh how much of the move reflects re‑rating versus short‑term enthusiasm, given past financings and ongoing development needs. Monitoring follow‑up data readouts and future capital decisions could help assess durability of gains above recent price levels.

Key Figures

Summit date: February 12, 2026 Fireside chat time: 10:00 a.m. ET (7:00 a.m. PT)

2 metrics

Summit date February 12, 2026 Date of Guggenheim Emerging Outlook: Biotech Summit 2026 participation

Fireside chat time 10:00 a.m. ET (7:00 a.m. PT) Scheduled time for ELDN’s fireside chat at the summit

Historical Context

5 past events · Latest: Jan 23 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 23	Phase 1b kidney data	Positive	-4.0%	Long-term Phase 1b tegoprubart kidney transplant data with favorable safety and eGFR.
Jan 08	Business update	Positive	+0.0%	2025 progress, 2026 tegoprubart outlook, and financing expected to fund into 2Q 2027.
Dec 01	Conference participation	Neutral	-6.1%	Announcement of participation in the 37th Annual Piper Sandler Healthcare Conference.
Nov 18	Islet transplant data	Positive	-4.9%	Preliminary tegoprubart data in islet transplant showing insulin independence with no major toxicities.
Nov 14	Earnings and financing	Neutral	-8.0%	Q3 2025 results, BESTOW Phase 2 data, and $57.5M equity financing for programs.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent ELDN news, even when clinically or strategically positive, has often coincided with flat or negative price reactions, pointing to a pattern of weak follow‑through on announcements.

Recent Company History

Over the last few months, ELDN has reported multiple clinically focused and corporate updates. On Nov 14, 2025, it paired Q3 2025 results with financing and Phase 2 BESTOW data. Subsequent news on Nov 18, 2025 and Jan 23, 2026 highlighted encouraging tegoprubart data in islet and kidney transplantation, while a Jan 8, 2026 outlook detailed funding into 2Q 2027. Despite these developments, most events were followed by flat or negative price moves, providing context for how today’s conference participation fits into a cautious trading backdrop.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steven Perrin, Ph.D., President and Chief Scientific Officer will participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 10:00 a.m. ET (7:00 a.m. PT).

To register in advance for the fireside chat webcast, sign up here.

A webcast replay will be accessible following the live session on the Company’s website under Events.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
CG Life
(212) 253 8881

jurban@cglife.com

Source: Eledon Pharmaceuticals

FAQ

When will Eledon (ELDN) present at the Guggenheim Emerging Outlook: Biotech Summit 2026?

Eledon will present on February 12, 2026 at 10:00 a.m. ET. According to Eledon, Steven Perrin, Ph.D. will join a fireside chat and the company will provide a live webcast and subsequent replay on its website for investors.

How can investors watch the Eledon (ELDN) fireside chat on February 12, 2026?

Investors can register for the live webcast in advance via the company’s registration link. According to Eledon, a replay will be posted after the live session on the company website under Events for later viewing.

Who from Eledon (ELDN) will speak at the Guggenheim Biotech Summit 2026 fireside chat?

Steven Perrin, Ph.D., President and Chief Scientific Officer, will participate in the fireside chat. According to Eledon, he will represent the company and discuss recent developments during the scheduled webcast session.

Will Eledon (ELDN) make presentation materials or a replay available after the Guggenheim summit?

Yes, a webcast replay will be accessible after the live session on the company website under Events. According to Eledon, investors unable to attend live can view the replay once it is posted online.